Compare TOWN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | EVO |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | Germany |
| Employees | 1939 | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | TOWN | EVO |
|---|---|---|
| Price | $37.23 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 685.3K | 61.9K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.63 | $1.37 |
| Revenue Next Year | $5.18 | $10.05 |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.91 | $1.90 |
| 52 Week High | $39.03 | $4.27 |
| Indicator | TOWN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 45.75 |
| Support Level | $34.48 | $1.90 |
| Resistance Level | $37.61 | $2.93 |
| Average True Range (ATR) | 0.72 | 0.04 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 55.78 | 100.00 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.